Harry Erba

2 months ago | onlinelibrary.wiley.com | Keith W Pratz |Harry Erba

1 Introduction Acute myeloid leukemia frontline therapy has evolved very little from the development of infusion cytarabine and daunorubicin (7 and 3) combinations described initially by Crowther in 1970 [1] and Yates in 1973 [2]. Of note, these studies reported complete remission rates of 60% and 65% respectively which is similar to CR rates currently seen with 7 and 3 in unselected AML patients.

Nov 20, 2024 | targetedonc.com | Harry Erba

Harry Erba, MD, PhD, professor of medicine at Duke Cancer Institute, chair of the SWOG Leukemia Committee, and co-chair of the myeloMATCH Senior Science Council, discusses the specific substudies included in myeloMATCH, a trial representing a significant shift in how acute myeloid leukemia (AML) is treated by addressing the disease's complexity and genetic diversity.

Oct 24, 2024 | onclive.com | Harry Erba |James McCloskey

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.

Oct 24, 2024 | onclive.com | Harry Erba |James McCloskey

Dose Intensity and Sequencing of Intensive Chemotherapy in Secondary AMLJames K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.

Oct 24, 2024 | onclive.com | Harry Erba |James McCloskey

Factors When Weighing Intensive Chemotherapy vs Other Regimens in Secondary AMLJames K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.